Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Occult breast cancer discovered due to a large mass in the axilla: a case report.
J Surg Case Rep
March 2025
Department of Thoracic Surgery and Breast Surgery, Asahikawa Medical University Hospital, 078-8510, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 078-8510, Japan.
Occult breast cancer (OBC) is a rare form of breast cancer that is detected due to regional lymph node metastasis in the axilla. The patient was a 77-year-old woman. Twenty-four years previously, she had undergone a breast-conserving surgery and axillary lymph node dissection for left breast cancer.
View Article and Find Full Text PDFCirculating short-chain and branched short-chain fatty acids and the risk of incident type 2 diabetes: findings from the 4C study.
Life Metab
April 2025
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Previous studies suggested that fecal short-chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) are associated with glucose regulation. However, the potential relationship between circulating SCFAs and BCFAs with incident diabetes risk in both men and women remains unidentified in prospective cohort studies. In this study, we examined a panel of nine serum SCFAs and BCFAs in 3414 subjects with incident diabetes, and matched normoglycemic controls from the China Cardiometabolic Disease and Cancer Cohort study.
View Article and Find Full Text PDFAdaptive neoadjuvant endocrine therapy screens out prime population of ribociclib intensive adjuvant therapy.
Chin J Cancer Res
January 2025
Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250017, China.
The latest data from the NATALEE trial showed the absolute 3-year invasive disease-free survival benefit was 4.9% between the experimental and control groups. That is to say, in the intermediate-risk hormone receptor positive/human epidermal growth factor receptor-2 negative subgroup, there are also some patients with primary resistance to ribociclib.
View Article and Find Full Text PDFClinicopathological and molecular features of HR /HER2 breast cancer patients with distinct endocrine resistance patterns.
Chin J Cancer Res
January 2025
Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Objective: Recurrence continues to be a pivotal challenge among hormone receptor-positive (HR)/human epidermal growth factor receptor 2-negative (HER2) breast cancers. In the international consensus guidelines, HR/HER2 breast cancer relapse patterns are divided into three distinct types: primary resistant, secondary resistant, and endocrine sensitive. However, owing to the lack of cohorts with treatment and follow-up data, the heterogeneity among different recurrence patterns remains uncharted.
View Article and Find Full Text PDFAdult Growth Hormone Deficiency (AGHD) and Outcomes (NordiNet and ANSWER).
J Endocr Soc
March 2025
Unit of Endocrinology, Medical Department, University Hospital, Universitätsmedizin Mainz, der Johannes Gutenberg Universität, 55131 Mainz, Germany.
Adult growth hormone deficiency (AGHD) is a rare disease with both physiological and psychological effects for untreated patients. AGHD symptoms can improve over time with GH treatment. Here we have analyzed the long-term effectiveness and safety of short-acting GH replacement therapy (GHRT) in treatment naïve and nonnaïve patients with AGHD using real-world data from the NordiNet® International Outcome Study and American Norditropin® Studies: Web Enabled Research Program.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!